Australia markets open in 4 hours 18 minutes

Fresenius SE & Co. KGaA (FRE.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
28.84+0.70 (+2.49%)
At close: 09:59PM CEST
Full screen
Previous close28.14
Bid28.93 x N/A
Ask28.96 x N/A
Day's range28.12 - 29.25
52-week range28.12 - 29.25
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Simply Wall St.

    Investors five-year losses continue as Fresenius SE KGaA (ETR:FRE) dips a further 3.8% this week, earnings continue to decline

    The main aim of stock picking is to find the market-beating stocks. But in any portfolio, there will be mixed results...

  • Reuters

    UPDATE 2-Fresenius raises outlook on strong quarterly results, exits Vamed

    German healthcare group Fresenius first-quarter results beat expectations, the company said on Wednesday, citing strong performance at its Kabi and Helios businesses, prompting it to raise its full-year outlook. First-quarter earnings before interest and tax (EBIT) were 633 million euros ($680 million), above analysts' expectations of 606 million euros, according to a consensus of forecasts from Vara Research. In a bid to get leaner, Fresenius also said that it would sell its investment unit, Fresenius Vamed, completing its portfolio restructuring.

  • Bloomberg

    Fresenius Sells Controlling Stake in Vamed Rehab Business to PAI

    (Bloomberg) -- Fresenius SE has agreed to sell a controlling stake in the rehabilitation business of its Vamed unit to French private equity firm PAI Partners as the German healthcare company further trims its portfolio.Most Read from BloombergSaudi Arabia Steps Up Arrests Of Those Attacking Israel OnlineTurkey Confirms All Trade Halt With Israel Over War in GazaHuawei Secretly Backs US Research, Awarding Millions in PrizesBiden Calls Ally Japan ‘Xenophobic’ Along With China, RussiaIn Jamie Dimo